LON:HCM - Hutchison China MediTech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 4,715 -20.00 (-0.42 %)
(As of 07/18/2018 05:47 AM ET)
Previous CloseGBX 4,735
Today's RangeGBX 4,700 - GBX 4,763
52-Week RangeGBX 2,840 - GBX 5,932
Volume509 shs
Average Volume13,897 shs
Market Capitalization£3.09 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hutchison China MediTech logoHutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorN/A
SymbolLON:HCM
CUSIPN/A
Phone+85221213888

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins2.91%
Return on Equity1.80%
Return on Assets2.14%

Miscellaneous

EmployeesN/A
Outstanding Shares66,440,000
Market Cap£3,090.00

The Truth About Cryptocurrencies

Hutchison China MediTech (LON:HCM) Frequently Asked Questions

What is Hutchison China MediTech's stock symbol?

Hutchison China MediTech trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

What price target have analysts set for HCM?

2 brokerages have issued 1 year price targets for Hutchison China MediTech's stock. Their forecasts range from GBX 3,840 to GBX 3,840. On average, they anticipate Hutchison China MediTech's stock price to reach GBX 3,840 in the next year. This suggests that the stock has a possible downside of 18.6%. View Analyst Ratings for Hutchison China MediTech.

What is the consensus analysts' recommendation for Hutchison China MediTech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hutchison China MediTech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Hutchison China MediTech's key competitors?

Who are Hutchison China MediTech's key executives?

Hutchison China MediTech's management team includes the folowing people:
  • Mr. Chi Keung To BSc, ACGI, MBA, Exec. Chairman (Age 66)
  • Mr. Christian Hogg BSc, MBA, CEO & Exec. Director (Age 52)
  • Mr. Johnny Cheng BEc, CA, CFO & Exec. Director (Age 51)
  • Ms. Edith Shih BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 66)
  • Mr. Mark Lee, Sr. VP of Corp. Fin. & Devel. (Age 41)

Has Hutchison China MediTech been receiving favorable news coverage?

Media stories about HCM stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hutchison China MediTech earned a news sentiment score of 0.15 on Accern's scale. They also gave news headlines about the company an impact score of 46.84 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Hutchison China MediTech?

Shares of HCM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hutchison China MediTech's stock price today?

One share of HCM stock can currently be purchased for approximately GBX 4,715.

How big of a company is Hutchison China MediTech?

Hutchison China MediTech has a market capitalization of £3.09 billion.

How can I contact Hutchison China MediTech?

The company can be reached via phone at +85221213888.


MarketBeat Community Rating for Hutchison China MediTech (LON HCM)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech and other stocks. Vote "Outperform" if you believe HCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.